INTRODUCTION
Astrocytes (AS) carry out general functions in the central nervous system (CNS), including blood-brain barrier formation, regulation of synaptogenesis, and the maintenance of metabolic, ionic, and neurotransmitter homeostasis (Allen, 2014; Allen and Barres, 2009; Matyash and Kettenmann, 2010) . Because AS are pervasive throughout the CNS and their processes tile within domains, they are key environmental determinants for neural circuits. We have proposed that regionally diversified AS could become ''optimized'' to enhance local function (Freeman and Rowitch, 2013; Molofsky et al., 2012) . Indeed, differences in AS morphology (Oberheim et al., 2012) and transcriptional profiles Doyle et al., 2008; Zhang et al., 2014) suggest that AS comprise distinct classes with potentially varied regional activities (Ben Haim and Rowitch, 2017; Khakh and Sofroniew, 2015) . Coordination of voluntary movement is complex and requires diversified motor neuron (MN) subtypes that form region-and muscle-specific interactions (Kanning et al., 2010) . Pattern formation underlies generation of MN diversity (Stifani, 2014) , and a similar region-restricted developmental mechanism is associated with specification and regional allocation of AS (Hochstim et al., 2008; Muroyama et al., 2005; Tsai et al., 2012) . However, the relationship between local AS specialization, neuron subtype selective support, and neural circuit function remains poorly understood.
Spinal cord aMNs fall into two broad classes along the anterior posterior axis. Slow aMNs (SaMNs) innervate type I muscle fibers and generate fatigue-resistant, low-force contractions while fast aMNs (FaMNs) project to type II fast-fatigable muscle fibers and produce brief, but high force outputs (Burke et al., 1971; Eccles et al., 1957) . Gamma MNs (gMNs) innervate muscle spindles to ensure proper muscle fiber tension. The morphological, transcriptional, and biophysical properties of these MN subtypes match their corresponding muscle contractile properties (Henneman, 1957; Kernell, 1966; M€ uller et al., 2014) . FaMNs are larger in size, are activated at higher thresholds, and fire action potentials in high-frequency bursts that are readily distinguishable from SaMNs (Hadzipasic et al., 2014) .
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscle weakness and paralysis resulting from MN death (Cleveland and Rothstein, 2001) . Although the majority of cases are sporadic, familial forms of ALS have provided insight into genetic causes of the disease (Robberecht and Philips, 2013) . Of these, constitutive mutations of superoxide dismutase 1 (SOD1) (Rosen, 1993) have been the most extensively studied and are sufficient to cause clinical symptoms and MN death in rodent models (Philips and Rothstein, 2015) . FaMNs innervating fast-fatigable muscle fibers are selectively vulnerable in ALS (Saxena and Caroni, 2011) . In SOD1G93A transgenic ALS mice, these MNs display early transcriptional alterations and endoplasmic reticulum (ER) stress (Saxena et al., 2009 ) and selectively express matrix metalloproteinase-9 (MMP-9), which regulates FaMN survival and disease progression (Kaplan et al., 2014) . Indeed, FaMN cell death in ALS is generally thought to cause loss of peak strength and clinical decline in both rodent models and human patients (Kanning et al., 2010; Kaplan et al., 2014; Pun et al., 2006) . MN death in ALS also involves non-cell-autonomous mechanisms due to glial cell dysfunction (Lobsiger and Cleveland, 2007) . For instance, selective removal of SOD1G37R in microglia (Boillé e et al., 2006) , oligodendrocyte precursor cells (Kang et al., 2013) , and AS (Yamanaka et al., 2008) slowed disease progression, suggesting that mutant SOD1 is detrimental to glial cell functions.
Is there a role for local ventral horn AS to selectively maintain the physiological properties and function of MN subtypes, and is this role disrupted in ALS? We have previously shown that ventral horn AS-encoded function of Sema3a is essential for the survival of aMNs . Here, we focused on the astrocytic inward-rectifying K + channel Kir4.1 (a.k.a. Kcnj10) , which is selectively enriched in ventral compared to dorsal spinal cord AS (Olsen et al., 2007) . Kir4 .1 and Kir5.1 are the major inward-rectifying K + channels expressed in AS and are important for K + homeostasis, establishing the characteristic high resting K + current and setting AS resting membrane potential (Djukic et al., 2007; Olsen et al., 2006; Seifert et al., 2009; Sibille et al., 2015) . Downregulation of AS Kir4.1 has been observed in several CNS diseases such as acute and chronic neuroinflammation (Schirmer et al., 2014; Zurolo et al., 2012) , spinal cord injury (Olsen et al., 2010) , and transgenic mouse models of ALS (Batavelji c et al., 2012; Kaiser et al., 2006) , raising the question of whether such dysregulation is pathological or maladaptive. Here, we report that AS Kir4.1 is specifically required to maintain functional properties-but not survival-of FaMN populations in the mouse spinal cord. AS Kir4.1 expression surrounding FaMNs was developmentally upregulated in a VGLUT1-dependent manner. Conditional knockout (cKO) of AS-encoded Kir4.1 (AS-Kir4.1cKO) led to a highly selective and pervasive reduction in FaMN size and characteristic electrophysiological properties. AS-Kir4.1cKO animals showed decreased fast-twitch muscle fiber size and peak strength. In contrast, SaMNs and gMNs showed no detectable abnormalities. Viral overexpression of Kir4.1 in AS was sufficient to increase both FaMN and SaMN soma size through activation of the PI3K/mTOR/pS6 pathway. In cultured AS derived from ALS patient-induced pluripotent stem cells (iPSCs), we observed significant reduction of KIR4.1 (KCNJ10) expression, suggesting that ALS-associated SOD1 mutation causes cell-autonomous downregulation of KIR4.1. Because AS Kir4.1 was dispensable for FaMN survival even in the mutant SOD1 ALS mice, we conclude that its function is required to maintain peak strength, FaMN cellular, and biophysical properties, but not MN survival. Collectively, these results suggest that clinical loss of peak strength in ALS could signify downregulation of AS Kir4.1 expression and therefore be uncoupled from FaMN cell death.
RESULTS

Kir4.1 Upregulation in Ventral Horn AS Surrounding FaMNs
To identify regions with the highest Kir4.1 expression levels, we analyzed mRNA expression profiling data from human (GTEx- Consortium, 2015) and mouse (Kasukawa et al., 2011) CNS. Kir4.1 transcript levels varied by more than 5-fold across CNS regions, with the highest expression in the spinal cord of both humans and mice (Figures 1A and 1B) , consistent with previous studies (Nwaobi et al., 2016; Olsen et al., 2007) . The spinal cord has well-defined organization in the dorsoventral (DV) axis with MNs located in the ventral horn ( Figures 1C and 1D ). Kir4 .1 showed marked expression in ventral gray matter as compared to dorsal horn in human ( Figure 1C ; Table S1 ) and mouse (Figures 1D and 1E) spinal cord. In mice, Kir4.1 was enriched in ventral versus dorsal AS in both cultured and fluorescenceactivated cell sorting (FACS)-purified AS from Aldh1l1-GFP mice Tien et al., 2012 ) ( Figure 1F) .
We determined the cell-type contributions to Kir4.1 expression in the mouse spinal cord using Aldh1l1-GFP mice to label AS along with markers of oligodendrocytes and neurons. We found an 8-fold enrichment of Kir4.1 mRNA in FACS-isolated AS compared to non-AS ( Figure 1G ), consistent with mRNA expression profiling data from human and mouse cortex (Figures S1A and S1B). Kir4 .1 was also expressed in approximately 30% of gray matter oligodendrocytes in the ventral horn, but not in NeuN + or choline acetyltransferase (ChAT) + neurons ( Figure 1D ; Figures S1C and S1D). Using MMP-9 as a marker of FaMNs (Kaplan et al., 2014) , we observed a graded expression pattern of Kir4.1 with highest levels surrounding MMP-9 + FaMNs as compared to MMP-9 À SaMNs ( Figures 1H and 1I ).
As Kir4.1 function is related to synaptic activity (Cheung et al., 2015) and neuronal signaling regulates the expression levels of other AS transporters (Muthukumar et al., 2014; Yang et al., 2009) , we investigated Kir4.1 expression in relation to the excitatory presynaptic terminal markers VGLUT1 (Figures S2A-S2D) and VGLUT2 ( Figure S2E ) in the developing mouse spinal cord. We observed correlated spatiotemporal expression of Kir4.1 with VGLUT1, but not VGLUT2, expression during development in the mouse spinal cord ( Figure S2 ). Interestingly, FaMNs have a larger VGLUT1 synaptic density than SaMNs (Basaldella et al., 2015) , consistent with the observed higher Kir4.1 expression levels around FaMNs (Figures 1H and 1I) . To determine whether VGLUT1 activity is required for AS Kir4.1 expression, we analyzed VGLUT1 À/À conventional KO animals (Morel et al., 2014) . We found that VGLUT1 loss of function led to dramatic reduction of AS Kir4.1 expression in ventral horn (Figures 1J and 1K) . Consistent with Kir4.1 expression dictated in part by neuron-derived factors, we found that spinal cord Kir4.1 (Kcnj10) levels were downregulated in a genetic MN ablation model at embryonic day 18.5 (E18.5) ( Figure S3 ). Together, these findings suggest that AS Kir4.1 expression levels show both regional (i.e., ventral versus dorsal horn) and subregional (i.e., FaMNs versus SaMNs) differences and are regulated in a VGLUT1-dependent manner in vivo. (G) Kir4.1 mRNA levels in P5 Aldh1l1-GFP + FACSpurified AS compared to Aldh1l1-GFP À non-AS cells from mouse ventral spinal cord (n = 3 mice, mean ± SEM, one-sample t test). (H) Kir4.1 protein is preferentially found around larger MMP-9 + FaMNs (white arrowheads) compared to smaller MMP-9 À SaMNs (yellow arrowheads) at P30 (scale bar, 50 mm). (I) Quantification of Kir4.1 signal intensity around individual MMP-9 + or MMP-9 À MN (n = 4 mice, >100 MN counts/animal, boxplot, Mann-Whitney test). (J) Kir4.1 loss in AS from VGLUT1 KO animals at P26. VGLUT1 KO mice were crossed with EAAT2td-Tomato reporter for AS visualization. (K) Quantification of Kir4.1 immunofluorescence intensity per AS (EAAT2-td-tomato + ) (n = 2 mice, >50 AS counts/animal, boxplot, Mann-Whitney test; scale bar, 40 mm, insert: 20 mm). *p < 0.05, **p < 0.01, ***p < 0.001. Edges of boxplots denote interquartile range (25 th -75 th percentile) with whiskers denoting 1.5 times the interquartile range and the black line denoting the median value. 2012), with a conditional floxed allele of Kir4.1 (Djukic et al., 2007) ( Figures S4A-S4C ). Aldh1l1-cre:Kir4.1 fl/fl animals, heretofore called AS- Kir4.1cKO , survived in normal numbers up to at least 1 year of age (data not shown). Mice were crossed with Aldh1l1-GFP reporter animals for AS visualization. AS Kir4.1 protein expression was undetectable in ventral horn gray matter AS of AS-Kir4.1cKO mice compared to cre-negative controls (Figures S4A-S4C); in contrast, Kir4.1 expression was preserved in 70% of oligodendrocytes in AS- Kir4.1cKO animals ( Figures S4A-S4C ). The number of Aldh1l1-GFP + AS was identical in AS- Kir4.1cKO and cre-negative control mice (data not shown). RNA sequencing (RNA-seq) of FACS-purified spinal cord Aldh1l1-GFP + AS from AS-Kir4.1cKO and cre-negative control mice showed that: (1) Kir4.1 (Kcnj10) was the most significantly downregulated transcript, whereas in contrast, (2) other AS differentiation genes, including glutamate transporters, showed non-significant changes (Figure S4D) . Although previous work showed that Kir4 .1-dependent maintenance of AS membrane potential was required for glutamate transporter-1 (GLT-1) function (Djukic et al., 2007) , we did not find any difference in total and GLT-1-mediated (+DHK) glutamate uptake between AS-Kir4.1cKO and cre-negative control spinal cords ( Figure S4E ). These findings indicate that Aldh1l1-cre drives AS loss of Kir4.1 function but does not change glutamate uptake/transporter expression. Moreover, we did not observe gliosis or microglial activation at any time points analyzed in AS-Kir4.1cKO mice ( Figures  S4F-S4H ).
AS-Encoded
Having confirmed AS Kir4.1 loss of function, we next focused on consequences for MN survival. AS- Kir4.1cKO and cre-negative controls were intercrossed with ChAT-GFP mice for MN visualization (Figure 2A ). We did not detect losses in FaMN, SaMN, or gMN populations in the lumbar spinal cord of AS-Kir4.1cKO mice compared to cre-negative controls at postnatal day 14 (P14), P30, and 6 months of age, as shown in Figure 2A . Thus, AS Kir4.1 is dispensable for the specification and survival of MNs. We next analyzed the morphological properties of MN subpopulations (Kanning et al., 2010) . While we observed normal mature soma sizes for all MN subtypes at P14 ( Figures 2B and 2C) , by P30 the largest ChAT + MN populations were no longer detectable in the lumbar (L3-L6) ventral spinal cord of AS- Kir4.1cKO mice. Indeed, we found a selective decrease in size of FaMNs at P30 and 6 months of age, whereas the size of SaMNs and gMNs remained unaffected ( Figures 2B-2G ). Retrograde labeling with cholera toxin subunit B (CTSB) of aMNs that innervate the tibialis anterior (TA) muscle, which contains primarily fast-twitch muscle fibers (Kaplan et al., 2014) , (H) Quantification of TA muscle fiber crosssectional area (n = 3 mice/group, >100 muscle fibers/animal, boxplot, Mann-Whitney test). (I-K) Abnormal muscle strength behavior in AS-Kir4.1cKO mice. Adult AS-Kir4.1cKO animals generate less peak force (>P50, n = 14-15 mice/ group, boxplot, Welch's t test) (I). AS- Kir4.1cKO animals have slower front and hindlimb movements as assessed by gait analysis with the catwalk behavioral test. Swing speed corresponds to the limb speed while in the air (same animals as in I, boxplot, Welch's t test) (J). AS-Kir4.1cKO animals display a shorter latency to fall on the accelerating rotarod at P30-P35 (n R 7 mice/group, mean ± SEM, two-way ANOVA, Bonferroni post hoc test) (K). Mice performed three trials (T, T2, and T3) per day on 3 consecutive days (D1, D2, and D3). *p < 0.05, **p < 0.01. Edges of boxplots denote interquartile range (25 th -75 th percentile) with whiskers denoting 1.5 times the interquartile range and black line denoting the median value.
confirmed reduced FaMN size in AS-Kir4.1cKO animals compared to cre-negative controls ( Figures 2H-2J ). Together, these findings indicate that the maintenance of large FaMN size has a selective dependence on AS Kir4.1. Figures S5C  and S5D ). Interestingly, these findings are consistent with FaMN physiological dysfunction and a shift toward ''slowlike'' properties ( Figure 3F ; Figures S5A and S5G) . Similarly, analysis of instantaneous firing frequency and steady-state firing frequency (at 33 rheobase), which distinguishes slow and fast MN properties (Hadzipasic et al., 2014) , showed that AS- Kir4.1cKO MNs are significantly more ''slow-like'' compared to control MNs ( Figures S5A and S5C) . AS- Kir4.1cKO MNs displayed a left shift of the current versus firing frequency curve in response to progressively increasing depolarizing currents ( Figure S5B ), which is also consistent with previously described ''slow-like'' MN properties (M€ uller et al., 2014) . We did not observe significant differences in the AHP amplitude ( Figure S5E ) or in the action potential height ( Figure S5F ) or half-width (data not shown). These findings indicate that maintenance of many FaMN biophysical properties depends on intact AS Kir4.1 expression/function ( Figure S5G ).
Loss of Fast
As previous studies have suggested a relationship between MN area and the size of the corresponding muscle fiber subset (Kanning et al., 2010) , we analyzed fast-and slow-twitch muscle fibers by histology. Indeed, we observed reduced fiber areas of the TA-a predominantly fast-twitch muscle-from AS-Kir4.1cKO mutants versus controls at P30 (Figures 3G and 3H) . In contrast, slow-twitch muscle fiber size was unchanged in these animals ( Figure 3H ).
We next studied the behavioral consequences of AS Kir4.1 deletion. Consistent with our observation that AS Kir4.1 was dispensable for MN survival, AS-Kir4.1cKO adult animals did not develop paralysis even at later time points (>1 year of age). Because FaMNs are necessary for the generation of maximal force output (M€ uller et al., 2014) , we used the grip strength test to measure peak force. We found that AS-Kir4.1cKO animals have decreased maximal peak force as compared with crenegative controls ( Figure 3I ). Consistent with this, AS-Kir4.1cKO mice showed slower front and hindlimb movements ( Figure 3J ) and were unable to run the fast speeds necessary to complete the accelerating rotarod task ( Figure 3K ). However, AS-Kir4.1cKO mice displayed normal spontaneous locomotor activity and basic movements in the open field test (data not shown). Together, these results suggest that AS Kir4.1 is selectively required for behavioral tasks involving strength or fast movements.
Kir4.1 Expression Is Reduced in Human ALS AS and Dispensable for MN Survival in SOD1G93A ALS Mice
Previous work reported a progressive decrease of Kir4.1 expression in the spinal cord of SOD1G93A ALS mice (Kaiser et al., 2006) , which exhibit a selective loss of FaMN populations (Kaplan et al., 2014; Pun et al., 2006) . To ascertain whether SOD1 mutation is sufficient to decrease KIR4.1 expression in human AS, we investigated iPSC-derived AS from ALS patients and controls ( Figure 4A ; Table S2 ). As shown in Figures 4B-4E , we observed significantly decreased KIR4.1 expression in cultured human AS carrying the SOD1D90A mutation. KIR4.1 levels were downregulated both at the mRNA level as shown by qPCR ( Figure 4C ) and at the protein level showed by western blot (Figures 4D and 4E ). Loss of KIR4.1 expression in human SOD1D90A mutant iPSC-AS appears selective, as ALDH1L1 and GFAP expression tended toward upregulation ( Figures 4D and 4E) . These findings in human patient-derived AS (in the absence of neurons) indicate that mutant SOD1 downregulates KIR4.1 in a cell-autonomous manner.
While AS-Kir4.1cKO did not cause MN cell death in wildtype (WT) background mice (see above), it was possible that AS Kir4.1 could influence cell loss in the more stressful setting of ALS. To rule out a requirement for AS Kir4.1 to maintain MN survival in an animal model of ALS, we assessed MN populations in WT, SOD1G93A (mSOD1), and AS- Kir4.1cKO, SOD1G93A (mSOD1, cKO) compound transgenic animals ( Figure 4F ). In keeping with prior reports (Vinsant et al., 2013) , we observed MN loss in mSOD1 mice at P80; however, we found no evidence for exaggerated losses in total MN or FaMN numbers in compound transgenic versus mice with SOD1G93A mutation alone ( Figures 4G-4I) . These findings indicate that AS Kir4.1 is dispensable for MN survival at P80 even in the setting of mutant SOD1G93A mutation. 
Kir4.1 Overexpression in Spinal Cord AS Promotes Non-selective Increases in aMN Size
We next used an AS-selective gainof-function approach in spinal cord to evaluate the effect of Kir4.1 on MN size. Adeno-associated viral (AAV) vectors encoding Kir4.1-eGFP or td-Tomato under the control of an AS-specific promoter (gfa-ABC 1 D) (Tong et al., 2014) were injected into lateral ventricles in neonatal mice at P2-P3, which progresses into the spinal canal. As shown (Figures 5A and 5B; , this strategy specifically promoted td-Tomato reporter and Kir4.1-eGFP expression in spinal cord ventral horn AS, but not neurons, microglia, or oligodendrocytes. AS Kir4.1 overexpression was sufficient to increase the size of FaMNs and SaMNs at 2 months post injection (Figures 5C-5E ). MNs abutting Kir4.1-eGFP-transduced AS were significantly larger, suggesting a contact-mediated effect ( Figures 5F and 5G ). We conclude that AS Kir4.1 overexpression is sufficient to increase the size of both FaMNs and SaMNs.
AS Kir4.1 Regulates MN Size through the PI3K/mTOR/ pS6 Pathway The PI3K/mTOR/pS6 pathway is a known regulator of neuronal size. For example, knockout of the mTOR negative regulator PTEN results in increased neuro-axonal size in mice (Backman et al., 2001; Fricano et al., 2014; van Diepen et al., 2009) and in humans (Kwon et al., 2001; Marsh et al., 1999) with Lhermitte-Duclos disease. As shown ( Figures 6A-6D ), we found that levels of the mTOR effector phosphorylated ribosomal protein S6 (pS6) were decreased in MMP-9 + FaMNs in P30 AS- Kir4.1cKO (loss-of-function, LOF) mice and increased in P60 AAV-Kir4.1-injected (gain-of-function, GOF) mice. While pS6 levels tracked with MN soma area across groups, strong correlation was lacking at the single-cell level, suggesting that mTOR signaling was a driver rather than biomarker proxy of cell size ( Figure S7 ; STAR Methods). To determine whether the PI3K/mTOR/pS6 pathway was necessary for the increase in MN size observed with GOF, AAV-Kir4.1-eGFP, and AAVtd-Tomato-injected mice were treated with the mTOR inhibitor rapamycin or vehicle for 15 days (Figure 6E) . Indeed, rapamycin treatment prevented the AAV-Kir4.1-mediated increase in ChAT + and MMP-9 + MN size that were reduced to levels observed in AAV-td-Tomato controls ( Figures 6F-6H) .
Previous studies have shown that Kir4.1 loss or downregulation leads to deficits in AS K + uptake (Djukic et al., 2007; Olsen et al., 2006; Seifert et al., 2009 ) and increased extracellular K + (Tong et al., 2014) . To address whether extracellular K + might directly regulate MN soma size, we incubated acute spinal cord slices from P11-P12 WT mice in 3 mM KCl ACSF (control), 12 mM KCl ACSF (high KCl), or 5 mM mannitol (control for hyperosmotic solution) for 2 hr ( Figure 6I ). ChAT + MNs were smaller in the high K + condition compared with isotonic ACSF and hyperosmotic mannitol ACSF controls, suggesting a specific effect of K + in regulation of cell size ( Figures 6J and 6K) . These findings suggest a model where AS Kir4.1 regulates MN morphology via PI3K/mTOR/pS6 signaling (Figure 7) .
DISCUSSION
Recent studies support the emerging concept that AS functional diversification is tailored to particular CNS regions to optimize local neural circuit function (Ben Haim and Rowitch, 2017; Khakh and Sofroniew, 2015; Schitine et al., 2015) . Spinal MNs display a large diversity of morphological and physiological properties, providing a basis for selection of specialized AS engaged in synapse modulation , MN survival , and neuronal function (Freeman and Rowitch, 2013) . Here, we found that AS-encoded Kir4.1 is regionally distributed in the ventral horn with particular localization surrounding FaMNs. Loss of AS Kir4.1 function led to a selective decrease of FaMN size and to deficits in FaMN physiological function; we observed reduced fast-twitch muscle fiber size and peak strength without affecting FaMN survival. Our findings show that it is possible to uncouple loss of peak strength from FaMN death with implications for diseases like ALS. Indeed, in other pathological conditions, AS Kir4.1 downregulation is associated with neuroinflammation (Nwaobi et al., 2016) , suggesting that this is a more general maladaptive phenomenon resulting in neurological disability and might also explain why neurological function improves with resolution of neuroinflammatory lesions. 
Ventral Horn AS Kir4.1 Function Indicates a Subtype-Specific Relationship with FaMNs
Although the relative importance of AS inward-rectifying K + channels compared to AS Na + /K + -ATPase transporters in maintaining extracellular K + levels is a matter of debate (for review, see Larsen and MacAulay, 2014) , it is clear that Kir4.1 is required to establish the high K + conductance and hyperpolarized resting membrane potential of AS (Djukic et al., 2007; Seifert et al., 2009) , which are both important properties for the AS uptake of neuronal activityreleased K + . For example, in vivo studies have shown that Kir4.1 loss leads to altered extracellular K + dynamics in the hippocampus (Chever et al., 2010) and that restoration of Kir4.1 in striatal AS is sufficient to rescue extracellular K + increase in a transgenic mouse model of Huntington's disease (Tong et al., 2014) . Previous work indicated that global or glial-restricted KO of Kir4.1 (using the hGFAP promoter) results in early animal lethality by P30 with severe white matter pathology (Djukic et al., 2007; Neusch et al., 2001) . However, it is difficult to determine the cell-type-specific contribution of Kir4.1 in these studies as Kir4.1 was removed from both AS and oligodendrocytes. In our work, using Aldh1l1cre to target AS, we observed near total loss of Kir4.1 expression in ventral horn AS, whereas expression in oligodendrocytes was relatively preserved; thus, specific targeting of the astroglial lineage with Aldh1l1-cre most likely accounts for reduced severity of the phenotype in our study in which animals survived for at least 1 year of age.
Given the importance of AS-encoded inward-rectifying K + channel function in homeostasis, we surmised it would be required for optimal activity by all MN groups. However, we were surprised to find highly MN subtype-specific effects of AS- Kir4.1cKO . We found that AS-encoded Kir4.1 was specifically needed for the function of fast, but not slow, aMNs and that its loss did not appear to affect gMNs. While numbers of aand gMNs were normal and survival over time of all FaMNs, SaMNs, and gMNs populations was not altered, we observed a selective impact of Kir4.1 loss of function on FaMNs. AS-Kir4.1cKO resulted in biophysical changes indicative of FaMN dysfunction, a conclusion further supported by loss of fast-twitch muscle mass and peak strength. Viral-mediated overexpression of Kir4.1 in spinal AS led to a non-selective increase in the size of both FaMNs and SaMNs, with a more prominent effect in MNs directly abutting transduced AS. The fact that increased AS Kir4.1 is sufficient to promote and maintain both slow and fast aMN size suggests that AS Kir4.1 levels are optimized to specific neuronal subpopulations and is consistent with our observation of selective Kir4.1 upregulation surrounding FaMNs.
Ventral Horn AS-Encoded Kir4.1 Regulates FaMN Size through PI3K/mTOR/pS6 Signaling The PI3K/mTOR/pS6 signaling pathway regulates metabolism and cell size (Backman et al., 2001; Fricano et al., 2014; van Diepen et al., 2009) . Our data indicate that Kir4.1-driven increases in aMN size are PI3K/mTOR/pS6 pathway dependent. First, changes in the mTOR downstream effector pS6 parallel changes in MN size in both GOF and Kir4.1 LOF models. Second, GOF studies showed that Kir4.1-driven increase in cell size was reversed by the mTOR inhibitor rapamycin in vivo.
Might Kir4.1 have other effects in AS relevant to MN size and activity regulation? We took a comprehensive approach to this question by performing an RNA-seq profiling of FACSpurified AS from AS-Kir4.1cKO animals and control mice. These studies showed that, apart from Kir4.1 levels itself, Kir4.1cKO AS maintain other differentiated characteristics in vivo. In addition, we found no evidence for astrogliosis or microglial activation at any time points analyzed in AS-Kir4.1cKO mice. Prior studies have shown an association between Kir4.1 and glutamate uptake (Djukic et al., 2007; Kucheryavykh et al., 2007) ; however, three lines of evidence indicate that deficiency in glutamate uptake is unlikely to explain the MN phenotype observed in AS-Kir4.1cKO mice.
First, we found no evidence for dysregulated glutamate uptake in spinal cord synaptosomes from AS- Kir4.1cKO animals-a method validated in GLT-1 À/À animals (Tanaka et al., 1997 )-which probably relates to the fact that GLT-1 (Slc1a2) levels and transporter currents are approximately 10-fold lower in the spinal cord compared to hippocampus (Regan et al., 2007) . Second, RNA-seq profiling of FACSisolated AS from AS- Kir4.1cKO and control mice showed no difference in expression levels of glutamate transporters GLT-1 (Slc1a2) and Glast (Slc1a3). Third, AS-Kir4.1cKO animals survived up to 1 year of age without MN degeneration in contrast to GLT-1 -/animals (Rothstein et al., 1996; Tanaka et al., 1997) . Thus, AS Kir4.1 function does not result in prominent secondary changes in AS gene expression and measured glutamate uptake function. Our findings indicate region-specific AS Kir4.1 functions that interact specifically with FaMN populations. Such regionally adapted AS functions might comprise a general principle underlying their diversity.
Both Intrinsic and Extrinsic Cues Regulate AS Kir4.1 Expression in Development and Disease
The extent to which AS diversity is developmentally specified through pattern formation and/or induced locally by neuronal cues is unclear (Ben Haim and Rowitch, 2017) . For example, a recent study showed that Purkinje neuron-derived Sonic hedgehog regulates AS cell fate and Kir4.1 expression in cerebellum (Farmer et al., 2016) . Indeed, we found that developmental upregulation of ventral horn Kir4.1 was dependent on VGLUT1, suggesting that region-specific maturation of Kir4.1 is promoted by neuronal activity or associated factors. There might be a selective effect on Kir4.1 regulation by VGLUT1 synaptic terminal activity onto ventral horn MNs since VGLUT1 and Kir4.1 protein levels did not perfectly correlate in other parts of the spinal cord ( Figure S2A ) and brain regions, such as the cortex, that are known to have VGLUT1 activity but display lower levels of Kir4.1. However, in contrast to regulation by neuron-derived cues, AS diversification also obeys developmental patterning in vivo (Hochstim et al., 2008; Tsai et al., 2012) and in vitro (Krencik et al., 2011) .
As recent studies have demonstrated that increased extracellular K + decreases mTOR signaling in T cells (Eil et al., 2016) and that loss of AS Kir4.1 leads to increased extracellular K + (Tong et al., 2014) , we investigated whether extracellular K + could directly regulate MN cell size. In acute spinal cord slices, we found that increased extracellular K + was sufficient to reduce MN size, which suggests that AS Kir4.1 might regulate MN mTOR signaling and size through extracellular K + . In addition to K + , additional factors and mechanisms might be at play in Kir4.1-mediated MN size regulation. Indeed, Kir4.1 expression is selectively enriched in AS processes contacting MN soma, and MN size increase in Kir4.1 GOF mice was prominently in MNs directly abutting transduced astrocytes, suggesting that Kir4.1 effects could be partly contact mediated. Biophysical modeling studies have shown that AS Kir4.1 is particularly important for K + clearance during high levels of neuronal activity , which corresponds to the FaMN electrophysiological signature. These MNs also have a larger VGLUT1 synaptic density than SaMNs (Basaldella et al., 2015) . Hence, there might be an AS-MN subtype-specific crosstalk in the ventral spinal cord, where FaMN high activity/high VGLUT1 innervation drives AS Kir4.1 expression, which in turn decreases extracellular K + and modulates intrinsic MN mTOR signaling to control MN size.
Moreover, our study provides evidence that Kir4.1 is regulated in AS in a cell-autonomous manner. First, in vitro cultures with purified AS derived from neonatal spinal cord maintained ventral enrichment of Kir4.1 levels in the absence of neurons. Second, in cultured human iPSC-derived AS, we found that mutant SOD1 exerted cell-autonomous effects to downregulate KIR4.1. These findings suggest that interplay between intrinsic and extrinsic factors is needed to achieve optimal Kir4.1 expression during development. We speculate that patterning results in early relative upregulation of Kir4.1 in ventral AS domains and perhaps primes AS to detect neuronal activity-dependent cues that determine physiological Kir4.1 levels critical to maintain FaMN function and peak strength. It follows that maladaptive downregulation of Kir4.1 in disease would disrupt this support mechanism with functional compromise of FaMNs.
AS-Encoded Kir4.1 Uncouples Loss of Peak Strength from FaMN Death MN cell death is an irreversible step of clinical decline in ALS. FaMNs have been shown to be vulnerable in SOD1G93A mice (Kaplan et al., 2014; Pun et al., 2006; Saxena et al., 2009) . For example, loss of function of the FaMN-specific marker MMP-9 delays disease progression while its overexpression in FaMNs accelerated TA denervation (Kaplan et al., 2014) . Several studies indicate that mouse model and ALS patient-derived MNs have physiological alterations including intrinsic hyperexcitability (Devlin et al., 2015; Wainger et al., 2014) , hypoexcitability (Sareen et al., 2013) , or some combination depending on maturational state (Devlin et al., 2015) with still some considerable debate about what occurs in vivo (Sances et al., 2016) . In general, altered MN excitability is thought to contribute to chronic MN dysfunction as a common pathogenic feature in ALS.
By focusing on roles of AS, our study helps clarify the consequences of alterations in MN excitability and the importance of AS-encoded factors in regulating the clinical phenotype of peak strength in the following ways. First, while conditional KO of Kir4.1 in AS leads to an early dysregulation of MN excitability, we failed to observe any signs of MN loss through at least 6 months of age. This analysis contained counts of total MN numbers including FaMNs, SaMNs, and gMNs. These findings make the points that (1) alterations in MN excitability in ALS could be linked to impaired K + buffering by AS that downregulate Kir4.1 channels and (2) excitability dysregulation in AS- Kir4.1cKO animals is insufficient to cause MN cell death. Indeed, crossing AS-Kir4.1cKO into the SOD1G93A mutant background failed to accelerate MN loss in this animal model, suggesting that Kir4.1 is not essential for MN survival even in the setting of ALS. Second, loss of peak strength can be accounted for by AS-encoded Kir4.1 downregulation. Kir4 .1 expression is reduced in both mouse and rat SOD1G93A models in vivo (Batavelji c et al., 2012; Kaiser et al., 2006) , and in this study, we found that iPSC-derived AS from ALS patients show significant loss of Kir4.1 expression in vitro. Furthermore, as stated above, loss of Kir4.1 in AS causes a decrease of peak strength in the absence of MN cell death. Together, these findings suggest that loss of AS Kir4.1 in ALS is maladaptive and might underlie the initial clinical presentation of weakness. It follows that loss of peak strength early in the ALS disease course might represent pathology caused by Kir4.1 downregulation in AS. If so, this potentially ''reversible state'' could be treatable by gene overexpression to promote Kir4.1 expression in ventral horn AS to assuage muscle weakness. Together, these findings suggest the consequences of AS Kir4.1 loss on MN function in ALS and neuroinflammatory conditions.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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QUANTIFICATION AND STATISTICAL ANALYSIS
Motor Neuron Soma Size and Count Analysis
Motor neuron soma size and counts were performed on maximal intensity projections of 10 mm z stacks with a 2 mm z-step of lumbar (L3-L6) levels on 2-4 sections per animal. Soma size was determined by tracing the ChAT-GFP signal using ImageJ software. Measurements were performed on the optical section with the largest soma area and only on motor neurons that had a DAPI nucleus visible. Similarly, motor neurons were only counted if a DAPI + nucleus was present. Phopho-S6 fluorescence intensity (IR) was measured using the mean gray value function on ImageJ within a ROI delineating individual fast MMP-9 + MN soma, which assures value normalization according to the size of the selected area (i.e., MN soma). In addition, as immunofluorescence intensity can vary between sets of experiments (for example, depending on tissue fixation), the absolute values of pS6 IR were normalized to the value in their respective internal controls ( =1) for both LOF and GOF experiments. Quantifications were performed on 40x confocal images (12 mm z stack, 1 mm z-step) at the lumbar (L3-L6) spinal cord levels on 5-8 sections per mouse. For the contact/non-contact soma area ratio quantification, MN soma area was quantified on merged images with transduced astrocytes in both groups. A potential limitation to this analysis is the fact that contact was defined based on 16 mm-thick sections. There may still be contact from astrocytes out of the section, which could inflate the observed effect in what we are labeling as non-contacted MNs. All quantifications regarding MN number and soma area were performed under blind conditions for experimental group (genotype, viral vectors injection or treatment groups).
Astrocyte and Synaptic Puncta Quantification
For AS Kir4.1 intensity quantification in Aldh1L1-GFP-labeled AS ( Figure S2C ), we quantified signal on maximal intensity projections of 10 mm z stacks with a 1 mm z-step using cellular areas centered on Aldh1l1-GFP + AS somas in ImageJ, since Aldh1l1-GFP signal is restricted to the soma and primary processes. Synaptic area coverage of VGLUT1 and VGLUT2 synapses were similarly obtained from maximal intensity projections of 10 mm z stacks with a 1 mm z-step using the analyze particle function in ImageJ. Thresholds were set identically for each image. For AS Kir4.1 intensity measurements in EAAT2-Td-Tomato-labeled AS ( Figures 1J and 1K) , 3D reconstruction was performed on 10-12 mm z -stacks with a 0.5-1 mm z-step using the surface tool in Imaris software, as previously described (Morel et al., 2014) . The volume of individual AS can be directly measured from generated 3D domains in Imaris. To quantify Kir4.1 signal within each AS domain, individual domains were masked onto the Kir4.1 channel by setting all pixel signals outside the masked cell domain to zero so that only Kir4.1 signal within the masked AS domain remained. The Kir4.1 signal for each AS domain was quantified using ImageJ software. For AAV transduction quantification, td-Tomato + or GFP + area was normalized to the ventral horn total area. The mean fluorescence intensity was also quantified in the ventral spinal cord for the two groups.
Statistical Analysis
We did not perform statistics to pre-determine group sample size. However, the sample sizes used were similar to previously published studies by our group and others. All biological replicates (n) are derived from at least three independent experiments (except for the VGLUT1 KO experiment, n = 2). Unless otherwise specified, no data were excluded from analysis. All bar graphs are expressed as mean ± SEM. The normality of the data points was verified using the Shapiro-Wilk test and for variables that displayed normal distributions an unpaired Welch's t test to compare the difference in means between two groups. Two-way ANOVA tests and Bonferroni post hoc tests were used for the rotarod experiment ( Figure 6 ). When normality tests failed, non-parametric Mann-Whitney (two groups) or Kruskal-Wallis (more than groups) tests were used. All statistical tests were performed using the R software environment.
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